Searched for
PFIZER BAYER
Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage studyThe study, which followed patients for over five years, found that those who received the regimen were nine times more likely to have lit...- Bayer aims to help CureVac with COVID-19 vaccine output, says CEOThough inoculation campaigns have started around the world using various COVID-19 vaccines, many countries say their ability to get shots i...
- COVID-19 vaccine contender CureVac links up with BayerCureVac, based in the German city of Tuebingen, said last month that it expects first results by the end of March from its phase 3 clinical...
- Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billionGermany’s Bayer will pay $2 billion upfront and up to an additional $2 billion in milestone payments contingent on development achievements...
- MNCs outshine market, return 400 bps more in last 6 months“MNCs are now trading near the mean premium valuation," says Dhirendra Tiwari.
- Big pharma returning to US price hikes in January after pausePfizer has already announced plans to hike prices on 41 of its drugs in mid-January.
- Reckitt may consider buying Pfizer's unitReckitt Benckiser Group would consider acquiring Pfizer's consumer-health unit were it to come up for sale in the wake of the Viagra maker'...
- Indian patent law doesn't discriminate against US companies: IPAIndian Pharma Alliance (IPA) writes to Roy Waldron after he slammed country's IP policy as protectionist and discriminatory.
- Only 3% of patents filed by MNC pharma firms under dispute: StudyPatent experts say few drugmakers are challenging frivolous drug patents and the Indian patent office is actually liberal in granting paten...
- BDR Pharma seeks licence to sell version of Bristol-Myers Squibb cancer drugA BDR Pharma executive said that the firm has applied to sell a generic version of BMS's patented anti-cancer drug Dasatanib at a much lowe...
- Govt mulls new price formula for patented drugsThe Department of Pharmaceutical has come up with a formula to price patented drugs in order to end a constant irritant for global drug mak...
- Pfizer to appeal India decision to revoke cancer drug patentPfizer Ltd, the India unit of US drugmaker Pfizer Inc, will challenge the country's patent office for revoking a patent for its cancer drug...
- Boehringer may buy Pfizer's animal health businessIn July last year, the world's second biggest pharma company, Pfizer had announced a spin off of its animal health and nutrition business.
- Natco Pharma files India's first compulsory licence pleaNatco Pharma has applied for the country's first compulsory licence to sell a generic version of Bayer's patented medicine.
- Non-compliance with disclosure norms on patents may bring trouble for pharma companiesSeveral global drugmakers, including Pfizer, Roche and Bayer, have not met full mandatory disclosures of their patented medicines in India,...
- Natco may seek compulsory licence for Bayer's cancer drugNatco Pharma plans to seek a compulsory licence to make Bayer AG's Nexavar in India, invoking a provision in local laws that allows generic...
- Pfizer’s growth outlook seen strongThe Pfizer stock has offered better returns to investors than the Bombay Stock Exchange’s (BSE) benchmark index, the Sensex, over the past ...
- See a price target of 925-950 for Bayer Corp.: Gaurang ShahGaurang Shah, Asst VP, Geojit BNP Paribas Financial Services in a chat with ET Now gives his perspective on Bayer Corp.
- J&J bags Pfizer consumer health unit for $16.6bnPfizer said on Monday it had reached a definitive agreement to sell its consumer healthcare business to Johnson & Johnson for $16.6bn in ca...
- GSK to offer $15 bn for Pfizer unit: reportThe British-based pharmaceutical group GlaxoSmithKline (GSK) is planning to offer more than $15 billion dollars for the consumer health car...
Load More
